Lein is delighted to announce that it has closed the second and final tranche of its current funding round. This additional investment complements the funding received in October from UPF (the UMIP Premier Fund, managed by MTI) and the National Endowment for Science, Technology and the Arts (NESTA).
The investors in this second tranche consist of a syndicate of very experienced business angels. “Our angel investors bring a lot more to Lein than just their investment” explained Dan Daly, Director. “Together they have very broad business, commercial and financial experience along with expertise in medical devices and the more general healthcare market. This expertise will prove extremely beneficial to Lein over the long term”.
This additional funding will enable Lein to increase the scale of its next stage clinical trials, address new applications and push forwards more rapidly with the miniaturisation of its technology.
Shayan Motamedi Fakhr, a Ph.D. student in the School of Engineering Sciences at the University of Southampton, successfully completed his Industrial Mathematics Internship with Lein in November. The internship, facilitated by the Industrial Mathematics Knowledge Transfer Network, enables students to gain firsthand experience of working in industry. Shayan’s signal processing expertise and enthusiasm brought new insights to Lein’s work in data analysis.
Lein, developer of non-invasive optical measurement technology, announces that it has raised £1 million from the UPF (the UMIP Premier Fund, managed by MTI) and the National Endowment for Science, Technology and the Arts (NESTA).
The new investment in Lein is to enable the company to miniaturise its pain-free medical diagnostics technology so that in its next generation of clinical trials, the technology will be in the form of convenient, hand-held devices.
Alongside these technical advances Lein intends to undertake further clinical work on blood glucose monitoring, building on studies already undertaken at The Royal Berkshire Hospital.
Lein is delighted to announce that Dr Robin Taylor, Senior Engineer at Lein, received a commendation at this year's prestigious British Engineering Excellence Awards in the Design Engineer of the Year category.
The Awards aim to celebrate UK engineering excellence and promote quality engineering design and innovation. The winners were announced at the award ceremony at London's Globe Theatre on the 1st October 2009.
For this award, sponsored by element14, nominees had to have demonstrated the ability to produce innovative designs with transferable technology within strict commercial limits. The judges felt that the competition in this category was so strong that it was necessary to award a Highly Commended to Robin for his role in developing Lein's core technology.
Lein was invited by the National Innovation Centre of the NHS to exhibit at the Innovation Expo at the Excel Centre on the 18th and 19th June 2009. Lein exhibited its platform optical technology with particular emphasis on its non-invasive glucose meter.
The purpose of the Innovation EXPO was to accelerate the adoption and diffusion of innovation throughout the NHS. It was aimed at a broad audience interested in innovation in healthcare with a wide range of speakers, exhibits and seminars.
Lein has signed a contract with the Biophotonics Instrumentation Group at Durham University to sponsor a three-year PhD studentship under the EPSRC CASE award scheme. The project is to be managed by Professor John Girkin, who has extensive experience applying confocal measurements to biological systems. He will be supported by Professor Clive Wilson's research group at Strathclyde University, who have expertise in clinical imaging, drug delivery and pharmacokinetics.
The goal of the collaboration is to adapt Lein’s confocal technology and to apply it to the non-invasive measurement of the level of, and the diffusion characteristics of, pharmaceutical drugs in the body via the eye.
Last year Lein received support from the NHS National Innovation Centre (NIC) to undertake a small clinical trial at the Royal Berkshire Hospital RBH on its non-invasive glucose meter prototype and to miniaturise its scanning technology.
Following the successful completion of these initial projects the NIC has provided Lein and the RBH with further support to:
develop a miniature demonstrator of Lein’s technology;
undertake further clinical work to demonstrate the efficacy and specificity of Lein’s meter.
The role of the NIC is to speed up the development of pre-commercial technologies likely to benefit the NHS. More information about their work can be found at www.nic.nhs.uk.
Lein filed the seventh in its suite of patents to protect its innovative technology for making non-invasive measurements of the body via the eye. This new patent protects Lein’s method of accurately tracking the measurement beam within the eye.
“Accurate knowledge of the position of the measurement beam is key to Lein’s measurement process. This latest patent adds to our proprietary knowledge in this area and has many exciting applications in both the health care and industrial sectors” said Robin Taylor.
Lein successfully completes KTP with Durham University more
Lein featured in Optics.org more
Lein achieves ISO9001 certification more